Organon & Co [OGN] stock is trading at $10.19, up 1.49%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OGN shares have gain 4.41% over the last week, with a monthly amount glided 16.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Organon & Co [NYSE: OGN] stock has seen the most recent analyst activity on May 02, 2025, when Evercore ISI downgraded its rating to a In-line. Previously, JP Morgan downgraded its rating to Underweight on September 06, 2024, and elevated its price target to $20. On November 03, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $16 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $28 on September 21, 2023. Raymond James initiated its recommendation with a Outperform and recommended $33 as its price target on March 16, 2023. BofA Securities downgraded its rating to Underperform for this stock on October 14, 2022, and downed its price target to $25. In a note dated September 06, 2022, Piper Sandler upgraded an Overweight rating on this stock and revised its target price from $37 to $34.
Organon & Co [OGN] stock has fluctuated between $8.01 and $23.10 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Organon & Co [NYSE: OGN] shares were valued at $10.19 at the most recent close of the market. An investor can expect a potential return of 37.39% based on the average OGN price forecast.
Analyzing the OGN fundamentals
Organon & Co [NYSE:OGN] reported sales of 6.29B for the trailing twelve months, which represents a drop of -6.72%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 1.82 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of16.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.01 points at the first support level, and at 9.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.33, and for the 2nd resistance point, it is at 10.47.
Ratios To Look Out For
For context, Organon & Co’s Current Ratio is 1.67. Also, the Quick Ratio is 1.15, while the Cash Ratio stands at 0.21. Considering the valuation of this stock, the price to sales ratio is 0.42, the price to book ratio is 4.85 and price to earnings (TTM) ratio is 3.53.
Transactions by insiders
Recent insider trading involved COX CARRIE SMITH, Director, that happened on May 14 ’25 when 12469.0 shares were purchased. Chief Human Resources Officer, Falcione Aaron completed a deal on May 07 ’25 to buy 5500.0 shares. Meanwhile, Gen. Counsel & Corp. Secy. Weaver Kirke bought 8045.0 shares on May 06 ’25.
